Semaglutide for atrial fibrillation and weight loss
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study tests whether a weekly injection of semaglutide (the same drug in Wegovy and Ozempic) can help people with atrial fibrillation lose weight and improve their heart condition. It's for people with AF who also have obesity, and may or may not plan to have a heart procedure called catheter ablation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your BMI is 30 or higher (meaning you have obesity).
- You have atrial fibrillation (AF) that comes and goes or lasts for a while.
- You have not used GLP-1 medications (like Ozempic or Wegovy) or weight-loss drugs in the last 90 days.
- You have not had weight loss surgery, or lost more than 11 pounds in the last month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a weight management program helps people with a new type of irregular heartbeat (atrial fibrillation) and obesity. It aims to see if losing weight can improve heart rhythm and reduce the need for further treatment.
This study tests a new medication called AT673 combined with semaglutide (Wegovy) to help people with type 2 diabetes and overweight or obesity lose weight and improve blood sugar. It is for people who have tried diet and exercise to lose weight but haven't had success.
This trial tests whether taking semaglutide (a once-weekly injection for weight loss) before a heart procedure called catheter ablation helps people with atrial fibrillation. It may help those with excess weight or obesity who have not used this type of medication before.
This trial tests whether a weight loss medication (semaglutide) given before and after a first-time heart ablation procedure for atrial fibrillation can improve outcomes. It is for people who are overweight or obese and have certain related health conditions.
This study tests an injectable medication called semaglutide to help with weight loss in people with a BMI of 28 or higher who have struggled to lose weight before. It compares the study drug to a similar approved weight loss medicine (Wegovy).
This study tests a medication called semaglutide (which helps with weight loss) in people with obesity who have struggled to lose weight before. It will see how much weight participants can lose while taking the drug.
Hear when a new Overweight or Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.